PortView
Amplify Weight Loss Drug & Treatment (THNR) ETF Holdings & Analysis
ETFOther
What THNR does
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| Novo Nordisk A/S | 8.83% | |
| Eli Lilly & Co | 8.62% | |
| Regeneron Pharmaceuticals Inc | 6.20% | |
| Innovent Biologics Inc | 6.18% | |
| CSPC Pharmaceutical Group Ltd | 5.73% | |
| Amgen Inc | 5.69% | |
| Scholar Rock Holding Corp | 5.58% | |
| Merck & Co Inc | 5.54% | |
| AbbVie Inc | 5.17% | |
| Pfizer Inc | 5.01% |
Sector allocation
| Cash & Others | 0.12% |
| Financial Services | 0.59% |
| Healthcare | 99.29% |
Geographic allocation
| United States | 57.13% |
| China | 13.82% |
| Denmark | 12.43% |
| Switzerland | 4.95% |
| Japan | 4.14% |
| United Kingdom | 4.10% |
| South Korea | 2.71% |
| Other | 0.72% |
PortView Portfolio Insights
PortView analyzes how THNR fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze THNR in PortView →Related securities
Related stocks
Frequently asked questions
- What does THNR track?
- THNR is the Amplify Weight Loss Drug & Treatment ETF, a Other ETF.
- What is the expense ratio of THNR?
- Expense ratio data for THNR is shown on the page when available from our data provider.
- What are the largest holdings in THNR?
- Top holdings include NVO, LLY, REGN, 1801.HK, 1093.HK.
- How can PortView analyze THNR overlap with other ETFs?
- PortView computes the holdings overlap between THNR and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.